The evolving nmCRPC treatment landscape - what is the role of bicalutamide?
Description
Professor Philip Cornford, an expert in the field of nmCRPC and the EAU prostate cancer guidelines chair, speaks on the updated European Association of Urology (EAU) guidelines and shares his insights on the use of bicalutamide in the evolving non-metastatic castration-resistant prostate cancer (nmCRPC) treatment landscape.
Within this bitesize video, Professor Cornford explores:
-
His role as urologist in the management of nmCRPC patients
-
How nmCRPC patients were treated and monitored historically
-
The current and evolving nmCRPC treatment landscape
-
The potential benefits of treatment with second generation ARis
-
The impact of second generation ARi licencing on the use of bicalutamide in nmCRPC management
This video is organised and funded by Bayer plc.
Speakers
Professor Philip Cornford
Professor Philip Cornford trained in London and Liverpool and was appointed as Consultant Urological Surgeon in 2001 at Royal Liverpool and Broadgreen University Hospital NHS Trust. He is also Honorary Associate Professor at the University of Liverpool, UK. Professor Cornford’s clinical practice has focussed on urological malignancies while also actively contributing to research and recruiting to a number of clinical trials. He is Chair of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel and a member of the EAU Guidelines Office Board.
Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.
If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.
